Developing monoclonal antibody therapies for measles could lead to adverse pathogen evolution

Area of Science:

• Virology
• Immunology
• Public Health

Background:

• Measles resurgence necessitates novel treatment strategies.
• Monoclonal antibody (mAb) therapies are under development for measles treatment.

Purpose of the Study:

• To evaluate the potential impact of monoclonal antibody therapies on measles virus evolution.
• To assess whether the benefits of mAb therapies outweigh the risks of immune escape.

Main Methods:

• In silico modeling of measles virus evolution under therapeutic pressure.
• Analysis of viral genetic diversity and immune escape pathways.

Main Results:

• Monoclonal antibody therapies may exert selective pressure on the measles virus.
• This pressure could lead to the emergence of resistant viral strains.
• Potential for reduced efficacy of existing measles vaccines.

Conclusions:

• The development of monoclonal antibody therapies for measles requires careful consideration of evolutionary risks.
• Strategies to mitigate viral immune escape should be integrated into therapeutic development.
• Balancing therapeutic benefits against the long-term threat to vaccine-induced immunity is crucial.